Although direct evidence remains limited, novel antidiabetic therapies such as SGLT2 inhibitors and GLP-1 receptor agonists through improved metabolic control and modulation of host immune function could influence susceptibility to opportunistic ocular infections, including fungal keratitis. This evidence concerns the gene GLP1R and fungal keratitis.